Identifying state-specific species key to boost India's seafood exports: Minister
Singh underscored the importance of value addition in Indian seafood to enhance its export potential.
Speaking at the 'Seafood Exporters Meet 2025,' he highlighted the ongoing government initiatives being taken in the fisheries sector, including the development of a single-window system for better market linkages for all stakeholders, strengthening of High Seas and Exclusive Economic Zone (EEZ) fishing, and upgrading infrastructure, all aimed at further bolstering the fisheries sector.
The minister emphasised on Marine Products Export Development Authority's (MPEDA) pivotal role in navigating the tariff challenges faced by the industry and urged MPEDA, along with state governments, to conduct stakeholder consultations for accurate mapping of state-wise species-specific exports and identifying new export opportunities.
He also assured the stakeholders of the government's commitment to further strengthening Indian seafood exports.
Dr Abhilaksh Likhi, Secretary (Fisheries), MoFAH&D, highlighted that only about 10 per cent of India's seafood exports by value are currently value-added products, stressing the need to raise this share to 30–60 per cent in line with global benchmarks through enhanced domestic production or import-and-re-export strategies.
He expressed concern over the heavy dependence on a single species, Whiteleg shrimp which accounts for 62 per cent of export value but only 38 per cent of quantity.
Dr Likhi stated the urgency of reducing post-harvest losses and assured that issues related to tariff and non-tariff barriers would be addressed in coordination with the Department of Commerce, Ministry of External Affairs, and other relevant authorities.
He also called for targeted inputs to identify and finance infrastructure upgrades that would significantly boost value addition across the seafood export value chain.
India's annual fish production has witnessed a significant growth of 104 per cent, rising from 95.79 lakh tonnes in FY 2013-14 to 195 lakh tonnes in FY 2024-25.
Inland fisheries and aquaculture have emerged as key contributors, accounting for over 75 per cent of the total production.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
14 minutes ago
- Mint
'India's freedom of speech regulated by Israel?': Congress questions after envoy Reuven Azar ‘targets' Priyanka Gandhi
Congress leader Pawan Khera on Wednesday, launched a scathing attack on Israel Ambassador Reuven Azar after his criticism of Priyanka Gandhi Vadra, who had accused Tel Aviv of 'genocide' and criticising the Indian government for its 'silence' on the matter. In a strongly worded post on social media platform X, Khera slammed Reuven Azar, stating that him 'targeting' a sitting Member of the Indian Parliament is 'both unprecedented and intolerable.' The Congress leader further tagged S Jaishankar, questioning if 'freedom of speech in India' had now 'begun to be regulated from Israel." Following Priyanka Gandhi's post on X, Israeli Ambassador to India Reuven Azar accused the Congress leader of spreading 'deceit' and presented Israel's version of the conflict's toll. 'What is shameful is your deceit. Israel killed 25,000 Hamas terrorists. The terrible cost in human lives derives from Hamas's heinous tactics of hiding behind civilians, their shooting of people trying to evacuate or receive assistance and their rocket fire,' Azar said in his post. The Israeli diplomat's post comes after Priyanka Gandhi alleged that Israel 'murdered over 60,000 people, 18,430 of whom were children', starved hundreds to death, and was threatening to starve millions more. 'Enabling these crimes by silence and inaction is a crime in itself. It is shameful that the Indian Government stands silent as Israel unleashes this devastation on the people of Palestine,' she wroteon X, on Tuesday. Apart from Pawan Khera, Congress's Gaurav Gogoi also hit out at the Israeli ambassador, stating that the 'Parliament cannot remain a passive spectator.' "The disparaging comments made by a foreign Ambassador against a Member of Parliament of India is a serious breach of privilege. Even if the Union Government is silent, the Parliament cannot remain a passive spectator..." he said on X. Veteran Congress leader and former Union Minister Anand Sharma also strongly condemned the remarks of the Israeli Ambassador to India, "denying" the humanitarian crisis of Gaza, saying that the language used by the Israeli representative and "undiplomatic, distasteful and unacceptable," while the brutality, destruction of schools, hospitals and mass starvation is taking place. As Israel continues its bombardment, the IDF said it has approved the "framework" for a new offensive in the Gaza Strip, days after the security cabinet called for the seizure of Gaza City, reported AFP. On Tuesday, Gaza's Health Ministry reported that five more Palestinians have died from hunger, bringing the total number of starvation-related deaths to 227, including 103 children.
Mint
14 minutes ago
- Mint
Multibagger defence stock Data Patterns stock surges 225% in 3 years: Should you buy now?
Shares of defence stock Data Patterns India Ltd (DPIL) have given multibagger returns, rising 225 percent over the last three years since August 2022. The stock gained 42 percent in the past six months, reflecting a medium-term recovery, but has declined 13 percent over the last year. It lost 5 percent in August so far after a 9 percent fall in July. Before that, it gained 2 percent in June, 14.5 percent in May, 47 percent in April, and 17.5 percent in March, though it had fallen 35 percent in February and 10.6 percent in January. The defence stock hit a 52-week high of ₹ 3,778 in May 2025 and a low of ₹ 1,917.95 in February 2025. Recently, Defence Minister Rajnath Singh stated that India's defence production reached a record ₹ 1.50 lakh crore in FY25, up 18 percent from ₹ 1.27 lakh crore the previous year. Since 2019–20, production has surged 90 percent from ₹ 79,071 crore. Singh highlighted on X that 'these numbers indicate a robust 18 percent growth over the previous fiscal's output, and a staggering 90 percent increase since 2019–20.' Chennai-headquartered Data Patterns reported Q1FY26 profit after tax (PAT) of ₹ 26 crore, down 22 percent from ₹ 33 crore a year ago. Revenue slipped 5 percent to ₹ 99 crore from ₹ 104 crore in Q1FY25. Jefferies maintains a 'buy' rating with a price target of ₹ 3,400. It noted that Q1 sales missed expectations due to a ₹ 270 crore revenue deferment, which is expected in Q2. Despite this, the company maintained FY26 growth guidance of 20–25 percent. First-quarter order flow rose 4.8 times to ₹ 180 crore, with orders worth ₹ 320 crore so far. Jefferies expects in-house technology in the growing defence sector to triple topline and bottomline by FY30. Nuvama Institutional Equities retained its price target of ₹ 3,700, stating that DPIL missed revenue/EBITDA estimates by 25/33 percent due to customer approval delays, which should normalize in the upcoming quarters. Order inflows were ₹ 1.8 billion, while YTD FY26 OI was ₹ 3.2 billion versus ₹ 3.5 billion in FY25, pushing the backlog to ₹ 8.1 billion. FY26 guidance includes OI of over ₹ 10 billion, revenue growth of 25–30 percent, and operating margins of 35–40 percent. Choice Institutional Equities projects a 28 percent upside, assigning a target of ₹ 3,100. It highlighted the strong order book of ₹ 1,079 crore and a pipeline of ₹ 2,000–3,000 crore over 18–24 months, primarily in airborne radars, EW systems, seekers, and upgrade programs. Data Patterns invested ₹ 120 crore in new products, enhancing the total addressable market and substituting imports. Choice upgraded its rating to BUY from ADD, raising the target price from ₹ 2,915 to ₹ 3,100. Data Patterns India is a vertically integrated defence and aerospace electronics solutions provider, serving the indigenously developed defence products industry. Its offerings include COTS boards, ATE and test systems, space systems, and radio frequency and microwave solutions. The company designs COTS module products for rugged applications and automatic test equipment platforms. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
14 minutes ago
- Mint
Nifty Pharma index rises 1.9%: Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?
Stock Market Today: The Nifty Pharma index gained 1.9% during the intraday trades on Wednesday. Alkem and Zydus stood among key gainers that led the rally The Nifty Pharma Index gained almost 2% during the intraday trade on Wednesday amid a relief rally in the Indian stock market. The Nifty Pharma Index opened at 21,803.45 levels, higher than the previous day's closing price of 21,753.50. It continued to gain further to an intraday high of 22,171.05, which meant gains of almost 2% over the previous day's close. Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and Abbott India were among the key gainers that led to the rise in the Nifty Pharma pack. The US market remains critical for many Indian pharma companies. Sun Pharmaceuticals, Lupin , Dr. Reddy's, Aurobindo, Cipla, and many more derive a significant part of revenues from the US markets. Thus the danger of a 50% tax on pharmaceuticals looms, and this clearly poses a risk to the profitability of Indian pharmaceutical businesses, which rely on the US market for 30-50% of their sales. Most of these US revenues, however, come from the generic drug segment. Silver lining The silver lining remains as India remains cost-competitive compared to both the US and global peers, which should help mitigate some risks, said Ajit Banerjee, president and chief investment officer at Shriram Life Insurance. The domestic Indian pharma market (50% of the Indian pharmaceutical market) will remain unaffected by tariffs. Within the US, the impact on the generic formulations market is still uncertain, though Indian players already operate on thin margins. Tariffs could increase the drug shortages by eliminating competition in a market where pricing pressures are already intense, which could be a positive for Indian companies over the mid- to long-term, highlighted Banerjee While the recent executive order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. Any tariff action will depend on the outcome of the ongoing investigation under Section 232 of the Trade Expansion Act of 1962. Even if the India pharma tariff question is answered, Kotak Institutional expect the uncertainty to persist around whether the anticipated pharma tariffs (post the Section 232 investigation) would add to the country-specific one, definition of pharma/pharma products and then eventually how much of the tariffs are passed on and rolled back Bannerjee believes the US can either bring manufacturing back home or reduce drug prices, but not both simultaneously. Even before tariffs are finalized, the uncertainty can lead to delays in order commitments and impact sector sentiment and stock price thereby. The sector currently trades at a 1Y forward P/E of 29.7 times, above its 10-year average of 26.7x. We see tariff-induced volatility as a chance for investors to accumulate quality pharma stocks on dips, said Banerjee. Nifty Pharma has witnessed two weeks of selling pressure, especially after the recent U.S. tariff developments, as per analysts. The Pharma Index was trading near a support level on the daily time frame, where a pause in the decline was expected in the coming days, potentially leading the index towards 21,998. The outlook remains negative as long as the index fails to sustain above 22,380. On the downside, a break below 21,240 could push the index further towards the 20,380–20,140 zone, as per Kunal Kamble, Sr. Technical Research Analyst at Bonanza * Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
